Frankfurt - Delayed Quote EUR

Q-linea AB (publ) (3F8.F)

0.0010
+0.0009
+(900.00%)
At close: May 30 at 8:15:47 AM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Anders Ljunggren Managing Director 2.71M -- 1981
Mr. Stuart Gander Chief Executive Officer -- -- 1978
Mr. Christer Samuelsson CFO & IR -- -- 1962
Mr. Henrik Jacobson Chief Operating Officer -- -- 1969
Ms. Ulrika Stolpe HR Manager -- -- 1967
Mr. Jonas Melin Director Product Development -- -- 1976
Mr. Thomas Fritz Chief Commercial Officer -- -- 1964
Ms. Victoria Lerneryd Manager of QA/RA -- -- 1984

Q-linea AB (publ)

Dag Hammarskjölds väg 52 A
Uppsala, 752 37
Sweden
https://qlinea.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
97

Description

Q-linea AB (publ) engages in the development of instruments and consumables for infection disease diagnostics in the United Kingdom. The company offers ASTar, an antimicrobial susceptibility testing technologies used in the treatment of bloodstream infections and sepsis. It also develops Podler, a portable blood culture unit for incubating and detecting growth in blood bottles. It serves to physicians, hospitals, laboratories, healthcare payers and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.

Corporate Governance

Q-linea AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

July 10, 2025 at 5:30 AM UTC

Q-linea AB (publ) Earnings Date

Recent Events